These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33788389)

  • 1. Delayed-onset severe neurotoxicity related to blinatumomab in an adolescent patient with refractory acute lymphoblastic leukemia.
    Filippidou M; Avgerinou G; Katsibardi K; Gavra M; Pons R; Kattamis A
    Pediatr Blood Cancer; 2021 Jul; 68(7):e29040. PubMed ID: 33788389
    [No Abstract]   [Full Text] [Related]  

  • 2. Timing of intrathecal chemotherapy and blinatumomab impacts neurotoxicity in acute lymphoblastic leukemia.
    Lee BJ; Griffin SP; Doh J; Kongtim P; Chan A; O'Brien S; Jeyakumar D; Ciurea SO
    Am J Hematol; 2023 May; 98(5):E113-E115. PubMed ID: 36794446
    [No Abstract]   [Full Text] [Related]  

  • 3. Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
    Stein A; Franklin JL; Chia VM; Arrindell D; Kormany W; Wright J; Parson M; Amouzadeh HR; Choudhry J; Joseph G
    Drug Saf; 2019 May; 42(5):587-601. PubMed ID: 30565020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Building a better blinatumomab.
    Litzow MR
    Am J Hematol; 2024 Apr; 99(4):512-514. PubMed ID: 38366135
    [No Abstract]   [Full Text] [Related]  

  • 5. Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab.
    Parisi R; Cowen EA; Gu S; Dusza S; Pulitzer M; Geyer MB; King AC; Markova A
    Leuk Lymphoma; 2023 Sep; 64(9):1583-1587. PubMed ID: 37309201
    [No Abstract]   [Full Text] [Related]  

  • 6. Bispecific antibodies in acute lymphoblastic leukemia therapy.
    Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
    Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
    Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
    Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, who have been treated with Blinatumomab.
    Mikhailova E; Gluhanyuk E; Illarionova O; Zerkalenkova E; Kashpor S; Miakova N; Diakonova Y; Olshanskaya Y; Shelikhova L; Novichkova G; Maschan M; Maschan A; Popov A
    Haematologica; 2021 Jul; 106(7):2009-2012. PubMed ID: 33375769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis on the clinical efficacy and adverse reactions of blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia].
    Shi YJ; Han Y; Wang Y; Mao DF; Zhang JL; Xi R; Bai H; Wu T
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):516-519. PubMed ID: 37550212
    [No Abstract]   [Full Text] [Related]  

  • 10. Is blinatumomab now standard of care consolidation for patients with ALL?
    Luger SM
    Clin Adv Hematol Oncol; 2023 Jun; 21(6):281-283. PubMed ID: 37530632
    [No Abstract]   [Full Text] [Related]  

  • 11. CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis.
    Horst HA; Zugmaier G; Martinelli G; Mergen N; Velasco K; Zaman F; Kantarjian H
    Am J Hematol; 2023 Aug; 98(8):E222-E225. PubMed ID: 37345570
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A balancing act: Blinatumomab use in a rare occurrence of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia in an adolescent patient with Down syndrome.
    Rav ES; Wahba A; Patnaik A; Toruner G; Hittle A; Toepfer L; Roth M; Cuglievan B; Nunez C; McCall D
    Pediatr Blood Cancer; 2023 May; 70(5):e30191. PubMed ID: 36602024
    [No Abstract]   [Full Text] [Related]  

  • 14. The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.
    Ngo D; Otoukesh S; Stein AS; Forman S; Pullarkat V; Aldoss I
    Leuk Lymphoma; 2022 Nov; 63(11):2754-2756. PubMed ID: 35727173
    [No Abstract]   [Full Text] [Related]  

  • 15. Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Chang J; Shen YJ; Shi T; Wang HF; Jin J; Zhu HH
    Ann Hematol; 2023 May; 102(5):1275-1277. PubMed ID: 36892592
    [No Abstract]   [Full Text] [Related]  

  • 16. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis.
    Topp MS; Stein AS; Gökbuget N; Horst HA; Boissel N; Martinelli G; Kantarjian H; Brüggemann M; Chen Y; Zugmaier G
    Cancer Med; 2021 Apr; 10(8):2601-2610. PubMed ID: 33734596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Queudeville M; Schlegel P; Heinz AT; Lenz T; Döring M; Holzer U; Hartmann U; Kreyenberg H; von Stackelberg A; Schrappe M; Zugmaier G; Feuchtinger T; Lang P; Handgretinger R; Ebinger M
    Eur J Haematol; 2021 Apr; 106(4):473-483. PubMed ID: 33320384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinatumomab in Practice.
    Lantz J; Pham N; Jones C; Reed D; El Chaer F; Keng M
    Curr Hematol Malig Rep; 2024 Feb; 19(1):1-8. PubMed ID: 38060085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
    Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
    Halford Z; Coalter C; Gresham V; Brown T
    Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.